Differential involvement of IκB kinases α and β in cytokine- and insulin-induced mammalian target of rapamycin activation determined by Akt

Journal of Immunology

Volumn 180, Issue 11, 2008, Pages 7582-7589

  Dan, Han C ^a   Baldwin, Albert S ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; I KAPPA B ALPHA; I KAPPA B BETA; INSULIN; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; TUBERIN; TUMOR NECROSIS FACTOR; 2 MORPHOLINO 8 PHENYLCHROMONE; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; CHROMONE DERIVATIVE; CHUK PROTEIN, HUMAN; ENZYME INHIBITOR; I KAPPA B KINASE; IKBKB PROTEIN, HUMAN; MORPHOLINE DERIVATIVE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE; RAPAMYCIN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CANCER CELL; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; ANIMAL; CELL LINE; DRUG ANTAGONISM; METABOLISM; MOUSE; MOUSE MUTANT; PHOSPHORYLATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; CELL LINE; CHROMONES; ENZYME INHIBITORS; HUMANS; I-KAPPA B KINASE; INSULIN; MICE; MICE, MUTANT STRAINS; MORPHOLINES; PHOSPHORYLATION; PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SIROLIMUS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 47249125723     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.180.11.7582     Document Type: Article

References (34)

1. Avruch, J., K. Hara, Y. Lin, M. Liu, X. Long, S. Ortiz-Vega, and K. Yonezawa. 2006. Insulin and amino-acid regulation of mTOR signaling and kinase activity through the Rheb GTPase. Oncogene 25: 6361-6372.
2. Fingar, D. C., and J. Blenis. 2004. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 23: 3151-3171.
3. Hay, N., and N. Sonenberg. 2004. Upstream and downstream of mTOR. Genes Dev. 18: 1926-1945.
4. Wullschleger, S., R. Loewith, and M. N. Hall. 2006. TOR signaling in growth and metabolism. Cell 124: 471-484.
5. Glantschnig, H., J. Fisher, G. Wesolowski, G. Rodan, and A. Reszka. 2001. M-CSF, TNFα, and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase. Cell Death Differ. 10: 1165-1177.
6. Lee, D.-F., H.-P. Kuo, C.-T. Chen, J.-M. Hsu, C.-K. Chou, Y. Wei, H.-L. Sun, L.-Y. Li, B. Ping, W.-C. Huang, et al. 2007. IKKβ suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell 130: 440-455.
7. Ozes, O., H. Akca, L. Mayo, J. Gustin, T. Maehama, J. Dixon, and D. Donner. 2001. A PI3K/AktAnTOR pathway mediates and PTEN antagonizes TNF inhibition of insulin signaling through insulin receptor substrate-1. Proc. Nat. Acad. Sci. USA 98: 4640-4645.
8. Inoki, K., Y. Li, T. Zhu, J. Wu, and K.-L. Guan. 2003. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signaling. Nat. Cell. Biol. 4: 648-657.
9. Li, Y., M. N. Corradetti, K. Inoki, and K.-L. Guan. 2004. TSC2: filling the GAP in the mTOR signaling pathway. Trends. Biochem. Sci. 29: 32-38.
10. Manning, B. D., and L. C. Cantley. 2003. Rheb fills a GAP between TSC and TOR. Trends Biochem. Sci. 28: 573-576.
11. Sancak. Y., C. Thoreen, T. Peterson, R. Lindquist, S. Kang, E. Spooner, S. Carr, and D. M. Sabatini. 2007. PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol. Cell. 25: 903-915.
12. Vander Haar, E., S. Lee, S. Bandhakavi, T. Griffin, and D.-H. Kim. 2007. Insulin signaling to mTOR mediated by the Akt/PKB substrate PRAS40. Nat. Cell. Biol. 9: 316-323.
13. Hara, K., Y. Maruki, X. Long, K. Yoshino, N. Oshiro, S. Hidayat, C. Tokunaga, J. Avruch, and K. Yonezawa. 2002. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 110: 177-189.
14. Kim, D.-H., D. Sarbassov, S. Ali, J. King, R. Latek, H. Erdjument-Bromage, P. Tempst, and D. M. Sabatini. 2002. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110: 163-175.
15. Sarbassov, D., D. Guertin, S. M. Ali, and D. M. Sabatini. 2005. Phosphorylation and regulation of Akt/PKB by the Rictor-mTOR complex. Science 307: 1098-1101.
16. Kim, D.-H., D. Sarbassov, S. M. Ali, R. R. Latek, K. Guntur, H. Erdjument-Bromage, P. Tempt, and D. M. Sabatini. 2003. GβL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. Mol. Cell. 11: 895-904.
17. Hay, N. 2005. The Akt-mTOR tango and its relevance to cancer. Cancer Cell 8: 179-183.
18. Majumder, P. K., and W. R. Sellers. 2005. Akt-regulated pathways in prostate cancer. Oncogene 24: 7465-7474.
19. Manning, B. D., and L. C. Cantley. 2007. Akt/PKB signaling: navigating downstream. Cell 129: 1261-1274.
20. Vivanco, I., and C. L. Sawyers. 2002. The phosphatidylinositol 3-kinase pathway and human cancer. Nat. Rev. Cancer 2: 489-501.
21. Magnusson, C., and D. Vaux. 1999. Signaling by CD95 and TNF receptors: not only life and death. Immunol. Cell Biol. 77: 41-46.
22. Guertin, D. A., and D. M. Sabatini. 2005. An expanding role for mTOR in cancer. Trends Mol. Med. 8: 353-361.
23. Cantley, L. C., and B. G. Neel. 1999. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the PI3K/Akt pathway. Proc. Natl. Acad. Sci. USA 96: 4240-4245.
24. Downward, J. 1998. Mechanisms and consequences of activation of protein ki-nase B/Akt. Curr. Opin. Cell Biol. 10: 262-267.
25. Hayden, M., and S. Ghosh. 2004. Signaling to NF-κB. Genes Dev. 18: 2195-2224.
26. Kim, H. J., N. Hawke, and A. S. Baldwin. 2006. NF-κB and IKK as therapeutic targets in cancer. Cell Death Diff. 13: 738-747.
27. Bonizzi, G., and M. Karin. 2004. The two NF-κB activation pathways and their roles in innate and adaptive immunity. Trends Immunol. 25: 280-288.
28. Madrid, L., M. Mayo, J. Reuther, and A. S. Baldwin. 2001. Akt stimulates the transactivation potential of the RelA/p65 subunit of NF-κB through utilization of IKK and activation of mitogen activated protein kinase p38. J. Biol. Chem. 276: 18934-18940.
29. Sizemore, N., N. Lemer, N. Dombrowski, H. Sakurai, and G. Stark. 2002. Distinct roles of IKKaα and IKKβ in liberating NF-κB from IκB and in phosphor-ylating the p65 subunit of NF-κB. J. Biol. Chem. 277: 3863-3869.
30. Gustin, J., O. Ozes, H. Akca, R. Pincheira, L. Mayo, Q. Li, J. Guzman, C. Korgaonkar, and D. Donner. 2004. Cell type-specific expression of the IκB kinases determines the significance of PI3K/Akt signaling to NF-κB activation. J. Biol. Chem. 279: 1615-1620.
31. Dan, H. C., M. Adli, and A. Baldwin. 2007. Regulation of mammalian target of rapamycin activity in PTEN-inactive cancer cells by IKKα. Cancer Res. 67: 6263-6269.
32. Brunn, G., J. Williams, C. Sabers, G. Wiederrecht, J. Lawrence, and R. T. Abraham. 1996. Direction inhibition of the signaling of the mammalian target of rapamycin by the PI3-kinase inhibitors, wortmannin and LY294002. EMBO J. 15: 5256-5267.
33. Ziegelbauer, K., F. Gantner, N. Lukacs, A. Berlin, K. Fuchikami, T. Niki, K. Sakai, H. Inbe, K. Takeshita, M. Ishimori, et al. 2005. A selective novel low-molecular weight inhibitor of IκB kinase-β (IKKβ) prevents pulmonary inflammation and shows broad anti-inflammatory activity. Br. J. Pharmacol. 145: 178-192.
34. Dan, H. C., M. Sun, L. Yang, R. Friedman, X. Sui, C. Ou, M. Nellist, R. Yeung, D. Halley, R. Nicosia, et al. 2002. PI3K/Akt pathway regulates tuberous sclerosis tumor suppressor complex by phosphorylation of tuberin. J. Biol. Chem, 277: 35364-35370.